SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Rubenstein EB, Peterson DE, Schubert M, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004; 100: 20262046.
  • 2
    Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004; 100: 19952025.
  • 3
    Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis. Cancer. 2003; 98: 15311539.
  • 4
    Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001; 19: 22012205.
  • 5
    Yavuzsen T, Davis MP, Walsh D, LeGrand S, Lagman R. Systematic review of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol. 2005; 23: 85008511.
  • 6
    Bower JE. Prevalence and causes of fatigue after cancer treatment: the next generation of research. J Clin Oncol. 2005; 23: 82808282.
  • 7
    Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 2003; 97: 29192925.
  • 8
    Kepivance (palifermin) [package insert]. Thousand Oaks, CA: Amgen Inc; 2004–2005.
  • 9
    Wernerman J, Hammarqvist F. Glutamine: a necessary nutrient for the intensive care patient. Int J Colorectal Dis. 1999; 14: 137142.
  • 10
    Mates JM, Perez-Gomez C, Nunez de Castro I, Asenjo M, Marquez J. Glutamine and its relationship with intracellular redox status, oxidative stress and cell proliferation/death. Int J Biochem Cell Biol. 2002; 34: 439458.
  • 11
    Coeffier M, Marion R, Ducrotte P, Dechelotte P. Modulating effect of glutamine on IL-1beta-induced cytokine production by human gut. Clin Nutr. 2003; 22: 407413.
  • 12
    Coeffier M, Marion R, Leplingard A, Lerebours E, Ducrotte P, Dechelotte P. Glutamine decreases interleukin-8 and interleukin-6 but not nitric oxide and prostaglandins e(2) production by human gut in-vitro. Cytokine. 2002; 18: 9297.
  • 13
    Evans ME, Jones DP, Ziegler TR. Glutamine prevents cytokine-induced apoptosis in human colonic epithelial cells. J Nutr. 2003; 133: 30653071.
  • 14
    Bellon G, Monboisse JC, Randoux A, Borel JP. Effects of preformed proline and proline amino acid precursors (including glutamine) on collagen synthesis in human fibroblast cultures. Biochim Biophys Acta. 1987; 930: 3947.
  • 15
    Savarese DM, Savy G, Vahdat L, Wischmeyer PE, Corey B. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev. 2003; 29: 501513.
  • 16
    Peterson D, Stanek S, Maiti B, French C, Shah A. Pharmacokinetics (PK) of Saforis administered to healthy subjects and stem cell transplant (SCT) patients with WHO grade > 2 oral mucositis (OM) [Abstract 16–115]. Support Care Cancer. 2006; 14: 640.
  • 17
    Aquino VM, Harvey AR, Garvin JH, et al. A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplant. 2005; 36: 611616.
  • 18
    Cockerham MB, Weinberger BB, Lerchie SB. Oral glutamine for the prevention of oral mucositis associated with high-dose paclitaxel and melphalan for autologous bone marrow transplantation. Ann Pharmacother. 2000; 34: 300303.
  • 19
    Huang EY, Leung SW, Wang CJ, et al. Oral glutamine to alleviate radiation-induced oral mucositis: a pilot randomized trial. Int J Radiat Oncol Biol Phys. 2000; 46: 535539.
  • 20
    Jebb SA, Osborne RJ, Maughan TS, et al. 5-Fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation. Br J Cancer. 1994; 70: 732735.
  • 21
    Schloerb PR, Skikne BS. Oral and parenteral glutamine in bone marrow transplantation: a randomized, double-blind study. JPEN J Parenter Enteral Nutr. 1999; 23: 117122.
  • 22
    Skubitz KM. Glutamine as a potential treatment for the prevention of chemotherapy-induced mucositis. J Infus Chemother. 1994; 4: 6467.
  • 23
    Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004; 4: 277284.
  • 24
    Blijlevens NM, McCann S. Palifermin in myelotoxic therapy-induced oral mucositis: a viewpoint by Nicole M.A. Blijlevens(1) and Shaun McCann(2). Drugs. 2005; 65: 21472149.
  • 25
    Furst P, Albers S, Stehle P. Glutamine-containing dipeptides in parenteral nutrition. JPEN J Parenter Enteral Nutr. 1990; 14( Suppl): 118S124S.
  • 26
    Petit R, Shinal E, French C. AES-14 facilitates rapid intracellular transport of high levels of L-glutamine in mucosal epithelial cells [Abstract 2410]. Proc Am Soc Clin Oncol. 2000; 19: 612a.
  • 27
    Petit RG, Shinal E. Aesgen-14 (uptake-enhanced L-glutamine suspension) reduces severe mucositis in acute radiation model where aqueous L-glutamine suspension is ineffective [Abstract 2861]. Proc Am Soc Clin Oncol. 2002; 21: 261b.
  • 28
    Anderson PM, Ramsay NK, Shu XO, et al. Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplant. 1998; 22: 339344.
  • 29
    Anderson PM, Schroeder G, Skubitz KM. Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer. 1998; 83: 14331439.
  • 30
    Peterson DE, Petit RG. Phase III study: AES-14 in chemotherapy patients at risk for mucositis [Abstract 2917]. Proc Am Soc Clin Oncol. 2003; 22: 725.
  • 31
    Skubitz KM, Anderson PM. Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study. J Lab Clin Med. 1996; 127: 223228.
  • 32
    Sonis ST, Eilers JP, Epstein JB, et al. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group. Cancer. 1999; 85: 21032113.
  • 33
    World Health Organization. WHO handbook for reporting results in cancer treatment. Geneva, Switzerland: World Health Organization, 1979: WHO Offset Publication No. 48. Available at: http://whqlibdoc.who.int/offset/WHO_OFFSET_48.pdf Accessed on June 28, 2006.
  • 34
    Fleiss JL. The design and analysis of clinical experience. New York: John Wiley & Sons; 1986: 275279.
  • 35
    Keefe DM. Gastrointestinal mucositis: a new biological model. Support Care Cancer. 2004; 12: 69.